CryoPort, Inc. (NASDAQ:CYRX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• CryoPort, Inc. (NASDAQ:CYRX) has received an average rating of "Moderate Buy" from analysts, with a price target averaging around $12.56.
• Insider transactions revealed that Director Robert J. Hariri sold 25,000 shares at $9.71 each, leading to a 32.78% decrease in his ownership.
• Institutional investors have significantly increased their stakes in CryoPort, with Nisa Investment Advisors boosting holdings by 299.9% in the second quarter.

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $12.5556.

A number of equities analysts recently weighed in on CYRX shares. Leerink Partnrs raised shares of CryoPort from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 6th. Stephens started coverage on shares of CryoPort in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price target on the stock. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target on the stock in a report on Wednesday, August 6th. Weiss Ratings reissued a "sell (d+)" rating on shares of CryoPort in a report on Wednesday, October 8th. Finally, Leerink Partners raised shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target on the stock in a report on Wednesday, August 6th.

Insider Transactions at CryoPort

In other CryoPort news, Director Robert J. Hariri sold 25,000 shares of the company's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $9.71, for a total transaction of $242,750.00. Following the sale, the director directly owned 51,275 shares of the company's stock, valued at $497,880.25. This represents a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert Stefanovich sold 9,300 shares of the company's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the sale, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This trade represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,300 shares of company stock worth $366,381 over the last three months. 10.00% of the stock is owned by insiders.

Institutional Investors Weigh In On CryoPort

Institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its holdings in CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock valued at $27,000 after purchasing an additional 2,729 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock valued at $44,000 after purchasing an additional 4,375 shares during the last quarter. SBI Securities Co. Ltd. lifted its holdings in CryoPort by 548,750.0% during the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after purchasing an additional 10,975 shares during the last quarter. CWM LLC increased its position in shares of CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock valued at $69,000 after buying an additional 10,591 shares during the period. Finally, ProShare Advisors LLC bought a new stake in shares of CryoPort during the second quarter valued at about $75,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Stock Performance

NASDAQ CYRX opened at $10.63 on Friday. CryoPort has a 1 year low of $4.58 and a 1 year high of $11.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The firm has a market cap of $532.24 million, a price-to-earnings ratio of 7.99 and a beta of 1.61. The company has a fifty day moving average price of $9.43 and a 200-day moving average price of $7.65.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that CryoPort will post -0.99 EPS for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.